Optimized serial expansion of human induced pluripotent stem cells using low-density inoculation to generate clinically relevant quantities in vertical-wheel bioreactors.
Animals
Biomarkers
/ metabolism
Bioreactors
Cell Aggregation
/ drug effects
Cell Culture Techniques
/ instrumentation
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Cells, Cultured
Humans
Induced Pluripotent Stem Cells
/ cytology
Infant
Kinetics
Mice, SCID
Oxygen
/ pharmacology
Teratoma
/ pathology
bioreactor
expansion
human induced pluripotent stem cells (hiPSCs)
low-shear
serial-passage
Journal
Stem cells translational medicine
ISSN: 2157-6580
Titre abrégé: Stem Cells Transl Med
Pays: England
ID NLM: 101578022
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
26
11
2019
revised:
24
02
2020
accepted:
22
03
2020
pubmed:
24
5
2020
medline:
9
7
2021
entrez:
24
5
2020
Statut:
ppublish
Résumé
Human induced pluripotent stem cells (hiPSCs) have generated a great deal of attention owing to their capacity for self-renewal and differentiation into the three germ layers of the body. Their discovery has facilitated a new era in biomedicine for understanding human development, drug screening, disease modeling, and cell therapy while reducing ethical issues and risks of immune rejection associated with traditional embryonic stem cells. Bioreactor-based processes have been the method of choice for the efficient expansion and differentiation of stem cells in controlled environments. Current protocols for the expansion of hiPSCs use horizontal impeller, paddle, or rocking wave mixing method bioreactors which require large static cell culture starting populations and achieve only moderate cell fold increases. This study focused on optimizing inoculation, agitation, oxygen, and nutrient availability for the culture of hiPSCs as aggregates in single-use, low-shear, vertical-wheel bioreactors. Under optimized conditions, we achieved an expansion of more than 30-fold in 6 days using a small starting population of cells and minimal media resources throughout. Importantly, we showed that that this optimized bioreactor expansion protocol could be replicated over four serial passages resulting in a cumulative cell expansion of 1.06E6-fold in 28 days. Cells from the final day of the serial passage were of high quality, maintaining a normal karyotype, pluripotent marker staining, and the ability to form teratomas in vivo. These findings demonstrate that a vertical-wheel bioreactor-based bioprocess can provide optimal conditions for efficient, rapid generation of high-quality hiPSCs to meet the demands for clinical manufacturing of therapeutic cell products.
Identifiants
pubmed: 32445290
doi: 10.1002/sctm.19-0406
pmc: PMC7445025
doi:
Substances chimiques
Biomarkers
0
Oxygen
S88TT14065
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1036-1052Informations de copyright
© 2020 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.
Références
Nat Biotechnol. 2002 Sep;20(9):933-6
pubmed: 12161760
J Tissue Eng Regen Med. 2012 Jun;6(6):462-72
pubmed: 21761573
J Biol Eng. 2019 Sep 14;13:74
pubmed: 31534477
Nat Biotechnol. 2006 Feb;24(2):185-7
pubmed: 16388305
Nat Biotechnol. 2000 Apr;18(4):399-404
pubmed: 10748519
J Tissue Eng Regen Med. 2016 Nov;10(11):893-907
pubmed: 25758460
Nat Rev Drug Discov. 2017 Feb;16(2):115-130
pubmed: 27980341
Biotechnol Adv. 2011 Nov-Dec;29(6):815-29
pubmed: 21726624
J Biotechnol. 2016 Sep 20;234:71-82
pubmed: 27480342
Tissue Eng. 2006 Nov;12(11):3233-45
pubmed: 17518637
Nat Rev Mol Cell Biol. 2016 Mar;17(3):194-200
pubmed: 26908143
J Clin Invest. 2015 Jul 1;125(7):2551-7
pubmed: 26132109
Tissue Eng Part C Methods. 2012 Nov;18(11):831-51
pubmed: 22559864
Biotechnol J. 2015 Jan;10(1):83-95
pubmed: 25524780
J Biotechnol. 2019 Oct 10;304:16-27
pubmed: 31394111
Biotechnol J. 2015 Oct;10(10):1589-99
pubmed: 26110829
Tissue Eng Part C Methods. 2012 Oct;18(10):772-84
pubmed: 22519745
Stem Cells Dev. 2017 Dec 15;26(24):1804-1817
pubmed: 29017378
J Biotechnol. 2017 Mar 20;246:81-93
pubmed: 28131858
Stem Cells Transl Med. 2020 Sep;9(9):1036-1052
pubmed: 32445290
Stem Cell Res. 2013 Nov;11(3):1103-16
pubmed: 23973800
Nat Protoc. 2011 May;6(5):689-700
pubmed: 21527925
Nat Biotechnol. 2010 Apr;28(4):361-4
pubmed: 20351691
Stem Cell Reports. 2014 Apr 24;2(5):734-45
pubmed: 24936458
Stem Cell Res. 2014 Sep;13(2):202-13
pubmed: 25043964
SLAS Technol. 2018 Aug;23(4):364-373
pubmed: 29481762
Stem Cells Int. 2018 Nov 22;2018:7396905
pubmed: 30595701
Stem Cell Reports. 2018 Aug 14;11(2):485-496
pubmed: 30033087
Development. 2013 Jun;140(12):2457-61
pubmed: 23715538
Cells. 2019 Jan 07;8(1):
pubmed: 30621042
J Biotechnol. 2007 May 1;129(3):421-32
pubmed: 17306403
Cell Stem Cell. 2011 Apr 8;8(4):376-88
pubmed: 21474102
Nature. 2016 Jun 15;534(7607):310-2
pubmed: 27306170
J Tissue Eng Regen Med. 2015 Dec;9(12):1363-75
pubmed: 23728860
Biotechnol Prog. 2015 Nov-Dec;31(6):1600-12
pubmed: 26289142
Trends Biotechnol. 2012 Jun;30(6):350-9
pubmed: 22541338
J Tissue Eng Regen Med. 2018 Feb;12(2):e1076-e1087
pubmed: 28382727